Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Nov 9, 2020 Abeona Therapeutics Reports Third Quarter Financial Results View Press Release Oct 27, 2020 Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer View Press Release Oct 6, 2020 Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
